Ignite Creation Date:
2024-05-06 @ 1:50 PM
Last Modification Date:
2024-10-26 @ 1:21 PM
Study NCT ID:
NCT04148885
Status:
UNKNOWN
Last Update Posted:
2019-11-04
First Post:
2019-10-29
Brief Title:
A Trial of Paclitaxel Albumin-binding for Castration-resistant Prostate Cancer
Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
One-arm Multi-center Clinical Trial of Paclitaxel Albumin-binding Combined With Carboplatin for Castration-resistant Prostate Cancer
Status:
UNKNOWN
Status Verified Date:
2019-10
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
One-arm multi-center clinical trial of paclitaxel albumin-binding combined with carboplatin for castration-resistant prostate cancer
Detailed Description:
Prostate cancer is one of the most common malignant tumors of the male genitourinary system In 2017 the American Oncology Society will report that 161360 new prostate cancers were estimated accounting for 21 of male tumors ranking first in male new tumors 26730 death cancer death The rate is second only to bronchial lung cancer and colorectal cancer In China although the incidence of prostate cancer is lower than the world epidemiological level the incidence of prostate cancer in China has shown an increasing trend in recent years The latest statistics from the National Cancer Center 2017 the incidence of male prostate cancer is 24 which is a male malignant tumor Seventh place in the disease The taxane drug docetaxel showed good anti-tumor activity in castration resistant prostate cancer CRPC patients and paclitaxel combined with carboplatin also had a certain effect on CRPC However in clinical practice patients with prostate cancer are mostly old often accompanied by other underlying diseases poor physical status and poor tolerance in the use of docetaxel and paclitaxel Albumin-bound paclitaxel has more tumor-targeted enrichment than traditional paclitaxel and is less toxic Therefore this study intends to explore the efficacy and safety of albumin-bound paclitaxel combined with carboplatin in the treatment of CRPC providing a reference for the treatment options of CRPC in clinical practice
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None